E7386 enhances lenvatinib's antitumor activity in preclinical models and human hepatocellular carcinoma.

To study the antitumor and antiangiogenic activity of combining E7386 (an oral protein-protein interaction inhibitor targeting CREB-binding protein (CBP)/ß-catenin) with lenvatinib and explore a novel mechanism of action of E7386 that boosts antitumor response. Overall design: We transcriptomically profiled four HCC cell lines treated with DMSO or E7386 We transcriptomically profiled HCCs obtained from genetically engineered mouse models overexpressing MYC-lucOS;CTNNB1 and treated with Vehicle, E7386, Lenvatinib or E7386+Lenvatinib